BrainsWay Ltd. (TLV:BWAY)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.48B +115.2% |
| Revenue (ttm) | 162.56M +27.1% |
| Net Income | 20.69M +316.5% |
| EPS | 0.42 +213.1% |
| Shares Out | 39.22M |
| PE Ratio | 89.37 |
| Forward PE | 62.10 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,681 |
| Average Volume | 99,192 |
| Open | 3,784.00 |
| Previous Close | 3,784.00 |
| Day's Range | 3,682.00 - 3,784.00 |
| 52-Week Range | 1,444.00 - 4,110.00 |
| Beta | 0.32 |
| RSI | 55.76 |
| Earnings Date | Mar 11, 2026 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
News
BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technol...
BrainsWay (BWAY) Invests in Canadian Mental Health Clinics
BrainsWay (BWAY) Invests in Canadian Mental Health Clinics
BrainsWay down after investment in Canadian mental care provider
BrainsWay (BWAY) stock dips as the company agrees to invest in BrainStim Health, an operator of mental health clinics in Canada, for a minority stake. Read more here.
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care BURLINGTON, Mass. and...
BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc.
BrainsWay continues to activel y evaluat e similar investments in l eading North American m ental h ealth p roviders to raise awareness and e xpand a ccess to transformative care
BrainsWay (BWAY) Gains as Cigna Unit Eases TMS Therapy Access
BrainsWay (BWAY) Gains as Cigna Unit Eases TMS Therapy Access
BrainsWay gains as Cigna removes prior authorizations for depression therapy
BrainsWay (BWAY) stock rises as Cigna (CI) drops prior authorization for TMS depression therapy, removing a key hurdle for a treatment the firm markets. Read more here.
BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care
BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay (BWAY) Initiates 2-for-1 Forward Split of ADSs
BrainsWay (BWAY) Initiates 2-for-1 Forward Split of ADSs
BrainsWay to change in ADS ratio to 1-for-1, effective March 3
BrainsWay Announces Change in ADS-to-Ordinary Share Ratio
Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors Change in ADS ratio aimed at simpl...
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adul...
BrainsWay Announces FDA Approval of Neurolief's Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)
BrainsWay's strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed on...
BrainsWay (BWAY) Gains Expanded Insurance Coverage for Depression Treatment
BrainsWay (BWAY) Gains Expanded Insurance Coverage for Depression Treatment
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients New Premera Blue Cross Blue Shield® policy extends to both adolescent and adult depression patients
BWAY Shares Gain on Optum Expanding Deep TMS Coverage for Teens
BrainsWay stock rises after Optum expands Deep TMS coverage for adolescents, boosting reimbursement visibility.
BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS™
Optum Behavioral Health, a Health Services Company with Over 48 Million Covered Lives, Joins Growing List of Insurers Now Covering Deep TMS Depression Therapy for Adolescents Aged 15 and Older Optum B...
Brainsway Ltd Analyst and Investor Day Transcript
Brainsway Ltd Analyst and Investor Day Transcript
Are Options Traders Betting on a Big Move in BrainsWay Stock?
Investors need to pay close attention to BrainsWay stock based on the movements in the options market lately.
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript
BrainsWay Ltd. (BWAY) Analyst/Investor Day Transcript
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS™ Treatment December 1, 2025
BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation techno...
BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment
BrainsWay (BWAY) Kicks Off Clinical Trial for Alcohol Use Disorder Treatment
BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder
Multicenter, randomized, controlled study will evaluate Company's next-generation multichannel TMS technology in reducing heavy drinking and cravings Multicenter, randomized, controlled study will eva...
BrainsWay: High Growth Set To Persist
BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News
BrainsWay (BWAY) Receives Updated "Buy" Rating from Analysts | BWAY Stock News